6 August
Immune response from Moderna's updated Omicron vaccine persists for 3 months
Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.
The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.
Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.
The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.
Recommended
6 August
6 August
5 August
5 August
29 July
Top news
29 July
16 July
16 July
15 July